Skip to content

Contact +44 (0) 20 7060 7474 email us

OTC drugs

The Global OTC Pharmaceutical Market 2009-2024

 

Publication Date May 2009
Publisher Visiongain
Product Type Report
Pages 146
ISBN Number not applicable
Product Code VIS00101

Price

£1,499.00
approximately: $2,270 | €1,673

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

OTC pharma is influenced by changes in consumer spending - but significant commercial opportunities for OTC switching will drive market expansion worldwide our new report explains

General economic trends worldwide will affect the over-the-counter (OTC) pharma market from 2009 onwards, with both market restraints and opportunities present. In this new report - The Global OTC Pharmaceutical Market 2009-2024 visiongain notes that Rx-to-OTC switching and the continuing importance of emerging pharma markets will drive OTC sales growth from 2009 onwards. Our forecasts reveal that the OTC pharma market will grow significantly next decade. This report explains where future OTC switching will occur, providing you with the information that you need to understand the current OTC market and its future prospects. The potential of this market remains significant, despite general economic uncertainty, visiongain asserts.

The Global OTC Pharmaceutical Market 2009-2024 examines all the major categories of OTC pharmaceuticals, including:

  • Analgesics * for internal and external uses
  • Cough, cold and allergy preparations
  • Dermatology - including antifungal agents and hair-loss treatments
  • Gastrointestinal drugs - including those for acid-related disorders, laxatives and anti-diarrhoea preparations
  • Anti-obesity treatments
  • Smoking cessation aids
  • Others including contraceptives, statins and erectile dysfunction areas.

Demographic trends, lifestyles changes and clinical advances are transforming medicine and creating opportunities for therapeutic areas and drug types in OTC pharma. Consumers are increasingly willing to self-medicate, for convenience and cost savings in particular. New regulations are changing OTC retail channels and sales processes, including the range of products on offer. Importantly, governments and healthcare providers are promoting self-medication, viewing the process as a tool to help contain healthcare expenditure. Therefore the OTC pharma market holds high potential for continued growth in both mature and emerging geographical markets.

Taking advantage of such opportunities will take considerable skill in a crowded and competitive marketplace. Competing with private labels, gaining regulatory approval for further OTC switches and harnessing Web 2.0 in advertising are all challenges that are assessed in this report, along with other aspects of the market.

Comprehensive analysis of the OTC market area

The Global OTC Pharmaceutical Market 2009-2024 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, discussions of pipeline developments and analysis of commercial drivers and restraints, including a SWOT analysis. There are over 100 tables and figures included. The result is a comprehensive market- and industry-centred report, with detailed analyses and informed opinion to aid your work.

Why you should buy The Global OTC Pharmaceutical Market 2009-2024

Benefits from purchasing this report include:

  • Your receiving a comprehensive appraisal of the OTC pharmaceutical market in 2008, including sales revenues and market shares for OTC categories, the top 10 companies and the leading OTC brands
  • Your receiving sales forecasts and discussions covering the period 2009 to 2024, including the global OTC market, leading OTC brand forecasts, top OTC manufacturer forecasts and therapeutic category forecasts
  • Your viewing sales forecasts for leading national OTC markets worldwide
  • Your receiving coverage of OTC switching from 2009 onwards, with important developments that you cannot ignore
  • Your viewing strengths, weaknesses, opportunities and threats facing the industry, with an emphasis on commercial drivers and restraints.

You can order this report today

The Global OTC Pharmaceutical Market 2009-2024 will provide you with a greater understanding of the expanding OTC market worldwide. What effect will the current downturn in consumer spending have on the OTC market What are the OTC product market shares in each of the top-10 OTC companies Which will be the most-important Rx-to-OTC switches in future If you want to understand this important market, you can stay ahead by ordering this report today.

Contents

  • 1 Executive Summary
  • 2 Introduction to OTC Pharmaceuticals
    • 2.1 OTC Pharmaceuticals
    • 2.2 Key Features of OTC Pharmaceuticals
    • 2.3 OTC Switching
    • 2.4 Manufacture and Distribution of OTC Pharmaceuticals
    • 2.5 Regulation of OTC Pharmaceuticals
      • 2.5.1 United States
      • 2.5.2 Japan
      • 2.5.3 European Union
      • 2.5.4 Other Countries
    • 2.6 Major OTC Pharmaceutical Therapeutic Categories
    • 2.7 Analgesics
      • 2.7.1 Internal Analgesics
      • 2.7.2 External Analgesics
    • 2.8 Cough, Cold and Allergy Products
      • 2.8.1 Cough and Cold Remedies
      • 2.8.2 Anti-Allergy OTC Products
    • 2.9 Dermatological Products
      • 2.9.1 Minor Cuts and Wounds
      • 2.9.2 Acne
      • 2.9.3 Rashes, Itchy Skin, Dermatitis and Eczema
      • 2.9.4 Cold Sores
      • 2.9.5 Warts
      • 2.9.6 Fungal Skin Infections
      • 2.9.7 Haemorrhoids
      • 2.9.8 Other Dermatological Products
    • 2.10 Gastrointestinal Products
      • 2.10.1 Indigestion and Heartburn
      • 2.10.2 Anti-Diarrhoea OTC Pharmaceuticals
      • 2.10.3 Laxatives
      • 2.10.4 Anti-Emetic OTC Pharmaceuticals
      • 2.10.5 Anti-Obesity OTC Pharmaceuticals
    • 2.11 Smoking Cessation Aids
    • 2.12 Other OTC Pharmaceuticals
    • 2.13 Vitamins, Minerals and Supplements
  • 3 The Global OTC Pharmaceutical Market
    • 3.1 Global OTC Pharmaceutical Market
      • 3.1.1 The Global OTC Market in 2008
      • 3.1.2 Economic Downturn and OTC Switching: Global OTC Pharmaceutical Market Forecast, 2009-2024
      • 3.1.3 World OTC Market to Increase 75% from 2008 Value by 2024
    • 3.2 OTC Pharmaceutical Categories
      • 3.2.1 OTC Category Revenues and Market Share, 2008
      • 3.2.2 OTC Category Sales Forecasts, 2009-2024
    • 3.3 Leading OTC Pharmaceutical Brands
    • 3.4 Leading OTC Pharmaceutical Manufacturers
    • 3.5 Johnson & Johnson
      • 3.5.1 Johnson & Johnson?s OTC Pharmaceuticals and Nutritionals Franchise
      • 3.5.2 The Global OTC Leader: Johnson & Johnson?s 2008 OTC Sales Revenues and Market Shares
      • 3.5.3 Johnson & Johnson OTC Pharmaceutical Forecast, 2009-2014
      • 3.5.4 Tylenol: The Only Billion Dollar OTC Brand
      • 3.5.5 Tylenol Sales Forecast, 2009-2024
      • 3.5.6 Johnson & Johnson?s Nicorette Nicotine Replacement Therapy
      • 3.5.7 Nicorette Sales Forecast, 2009-2024
      • 3.5.8 Zyrtec OTC/Reactine: Johnson?s & Johnson?s Fastest-Growing Brand of 2008
      • 3.5.9 Other Leading Johnson & Johnson OTC Pharmaceuticals
    • 3.6 GlaxoSmithKline
      • 3.6.1 GSK Consumer Healthcare
      • 3.6.2 GSK is Second-Largest Global OTC Pharmaceutical Company: 2008 OTC Sales and Market Shares
      • 3.6.3 GSK OTC Pharmaceutical Forecast, 2009-2014
      • 3.6.4 Panadol: GSK?s International Analgesic
      • 3.6.5 Panadol Sales Forecast, 2009-2024
      • 3.6.6 Nicabate/NicoDerm/Nicorette/NiQuitin Smoking Cessation Brands
      • 3.6.7 Nicabate/NicoDerm/Nicorette/NiQuitin Sales Forecast, 2009-2024
      • 3.6.8 alli: Pioneer OTC-Switch Diet Aid
      • 3.6.9 alli Sales Forecast, 2009-2024
      • 3.6.10 Other GSK Products with Revenues over $100m
    • 3.7 Bayer
      • 3.7.1 Bayer Consumer Care
      • 3.7.2 Bayer?s OTC Pharmaceuticals: 2008 Sales and Market Shares
      • 3.7.3 Bayer OTC Pharmaceutical Forecast, 2009-2014
      • 3.7.4 Bayer Aspirin
      • 3.7.5 Bayer Aspirin Sales Forecast, 2009-2024
      • 3.7.6 Other Bayer OTC Pharmaceuticals
    • 3.8 Novartis
      • 3.8.1 Novartis OTC Pharmaceuticals
      • 3.8.2 Sales and Market Share of Leading Novartis OTC Products in 2008
      • 3.8.3 Novartis OTC Pharmaceutical Forecast, 2009-2014
      • 3.8.4 Voltaren
      • 3.8.5 Novartis? Nicotine Replacement Business
      • 3.8.6 Otriven, Theraflu, Excedrin and Lamisil: Other Leading Novartis OTC Brands
    • 3.9 Proctor & Gamble
      • 3.9.1 Proctor & Gamble OTC Pharmaceuticals
      • 3.9.2 Prilosec OTC
      • 3.9.3 Prilosec OTC Will Face Competition from Generics and Newer OTC Heartburn Drugs
      • 3.9.4 Vicks
      • 3.9.5 Vicks Market Forecast, 2009-2024
    • 3.10 Wyeth/Pfizer
      • 3.10.1 Wyeth Consumer Healthcare
      • 3.10.2 Wyeth OTC Pharmaceuticals: 2008 Sales and Market Shares
      • 3.10.3 Advil
      • 3.10.4 Advil Market Forecast, 2009-2024
    • 3.11 Sanofi-Aventis
      • 3.11.1 Sanofi-Aventis OTC Division
      • 3.11.2 Sales and Market Share of Sanofi-Aventis OTC Pharmaceuticals
    • 3.12 Reckitt Benckiser
      • 3.12.1 Reckitt Benckiser OTC Pharmaceuticals
      • 3.12.2 Sales and Market Share of Reckitt Benckiser OTC Pharmaceuticals
    • 3.13 Boehringer Ingelheim
      • 3.13.1 Boehringer Ingelheim Consumer Health Care
      • 3.13.2 Sales and Market Share of Leading Boehringer Ingelheim OTC Pharmaceuticals
      • 3.13.3 The Dulcolax Franchise
      • 3.13.4 Mucosolvan/Lasolvan and other Leading OTC Products
    • 3.14 Perrigo
      • 3.14.1 Perrigo Consumer Healthcare
      • 3.14.2 Perrigo OTC Pharmaceuticals
  • 4 OTC Switching
    • 4.1 Motivations for OTC Switching
    • 4.2 Recent OTC-Switching Activity
    • 4.3 The Future Prospects for OTC Switching
    • 4.4 Interview with Joshua P. Cohen, Ph.D., Senior Research Fellow at the Tufts Center for the Study of Drug Development
      • 4.4.1 Prospects for OTC Statins in the US
      • 4.4.2 Future OTC Switching Categories
      • 4.4.3 Prospects for Behind-the Counter in the US
      • 4.4.4 OTC Safety Issues
    • 4.5 Gastrointestinal OTC Switching
      • 4.5.1 H2-Blockers
      • 4.5.2 PPIs Focus of Gastrointestinal OTC Switching
      • 4.5.3 Omeprazole
      • 4.5.4 Lansoprazole
      • 4.5.5 Pantoprazole
      • 4.5.6 Esomeprazole
      • 4.5.7 Rabeprazole
      • 4.5.8 Anti-Obesity OTC Switches
    • 4.6 Cough, Cold and Allergy OTC Switching
      • 4.6.1 First Generation Antihistamines
      • 4.6.2 Second Generation Antihistamines
      • 4.6.3 Third Generation Antihistamine
      • 4.6.4 Fluticasone Propionate
    • 4.7 Analgesic OTC Switching
      • 4.7.1 Triptans
      • 4.7.2 What are the Prospects for OTC Switching of Triptans in the US?
      • 4.7.3 Arthritis Pain
    • 4.8 Dermatological Drugs
    • 4.9 Other OTC-Switching Categories
      • 4.9.1 Oral Contraceptives
      • 4.9.2 Cholesterol-Lowering Drugs
        • 4.9.2.1 OTC Statins
        • 4.9.2.2 The UK?s Zocor Heart-Pro
        • 4.9.2.3 The Road to OTC Statins in the US
        • 4.9.2.4 What are the Worldwide Prospects for Statin OTC Switching?
      • 4.9.3 Erectile Dysfunction Drugs
    • 4.10 OTC Switching: A Continuing Trend during 2009-2024
  • 5 Issues Affecting the OTC Pharmaceutical Industry
    • 5.1 SWOT Analysis of the OTC Pharmaceutical Industry
    • 5.2 OTC Switching
    • 5.3 Brand Identity and Private Labels
    • 5.4 Developments in OTC Retail Channels
    • 5.5 Will OTC Move Behind-the-Counter?
    • 5.6 Web 2.0 Advertising Opportunities
    • 5.7 Changing World Demographics
      • 5.7.1 Population Increase and ?Greying? of the World Population
      • 5.7.2 Emerging-Market Economies
    • 5.8 The Worldwide Downturn in Consumer Spending, 2009-2010
    • 5.9 Safety Concerns, Misuse and Abuse of OTC Pharmaceuticals
      • 5.9.1 Safety Concerns
      • 5.9.2 OTC Drug Misuse
      • 5.9.3 OTC Drug Abuse
      • 5.9.4 Impact on the OTC Industry
  • 6 Leading OTC Pharmaceutical Country Markets
    • 6.1 Leading OTC Country Markets in 2008
    • 6.2 Leading OTC Country Markets Forecasts, 2009-2024
    • 6.3 The US OTC Market
    • 6.4 The Japanese OTC Market
    • 6.5 European OTC Markets
    • 6.6 Emerging OTC Markets
  • 7 Conclusions
    • 7.1 The Global OTC Market in 2008
      • 7.1.1 Leading OTC Categories
      • 7.1.2 Leading OTC Brands
      • 7.1.3 Leading OTC Pharmaceutical Manufacturers
      • 7.1.4 Leading OTC Country Markets
    • 7.2 Global OTC Pharmaceutical Market Forecast, 2009-2024
      • 7.2.1 OTC Growth Drivers
      • 7.2.2 OTC Switching Activity
      • 7.2.3 Emerging OTC Markets
    • 7.3 Future OTC Market Dynamics
  • List of Tables
    • Table 2.1 OTC Internal Analgesic Active Ingredients
    • Table 2.2 OTC External Analgesic Active Ingredients
    • Table 2.3 Cough, Cold and Allergy OTC Pharmaceutical Active Ingredients
    • Table 2.4 Antifungal OTC Pharmaceutical Active Ingredients
    • Table 2.5 Indigestion and Heartburn OTC Pharmaceutical Active Ingredients
    • Table 2.6 Anti-Diarrhoea OTC Pharmaceutical Active Ingredients
    • Table 2.7 OTC Laxative Active Ingredients
    • Table 2.8 Nicotine Replacement Therapy OTC Formulations
    • Table 3.1 OTC and Prescription-Only Pharmaceutical Markets, 2008
    • Table 3.2 World OTC Pharmaceuticals Sales Forecast, 2009-2014
    • Table 3.3 World OTC Pharmaceuticals Sales Forecast, 2015-2024
    • Table 3.4 OTC Category Revenues and Market Share, 2008
    • Table 3.5 OTC Category Sales Forecast, 2009-2024
    • Table 3.6 Top Eight OTC Brands, 2008
    • Table 3.7 Top Ten OTC Pharmaceutical Manufacturers, 2008
    • Table 3.8 Johnson & Johnson OTC Brands: 2008 Sales Revenues and Market Share
    • Table 3.9 Johnson & Johnson Total OTC Pharmaceuticals Sales Forecast, 2009-2014
    • Table 3.10 Tylenol Products, 2009
    • Table 3.11 Tylenol Sales Forecast, 2009-2014
    • Table 3.12 Tylenol Sales Forecast, 2015-2024
    • Table 3.13 Nicorette Formulations (Johnson & Johnson), 2009
    • Table 3.14 Nicorette (Johnson & Johnson) Sales Forecast, 2009-2014
    • Table 3.15 Nicorette (Johnson & Johnson) Sales Forecast, 2015-2024
    • Table 3.16 GSK OTC Brands: 2008 Sales Revenues and Market Share
    • Table 3.17 GSK Total OTC Pharmaceuticals Forecast, 2009-2014
    • Table 3.18 Panadol Formulations, 2009
    • Table 3.19 Panadol Sales Forecast, 2009-2014
    • Table 3.20 Panadol Sales Forecast, 2015-2024
    • Table 3.21 Nicabate/NicoDerm/Nicorette/NiQuitin NRT Brands (GSK), 2009
    • Table 3.22 Nicabate/NicoDerm/Nicorette/NiQuitin (GSK) Sales Forecast, 2009-2014
    • Table 3.23 Nicabate/NicoDerm/Nicorette/NiQuitin (GSK) Sales Forecast, 2015-2024
    • Table 3.24 alli Sales Forecast, 2009-2014
    • Table 3.25 alli Sales Forecast, 2015-2024
    • Table 3.26 Bayer OTC Brands: 2008 Sales Revenues and Market Share
    • Table 3.27 Bayer Total OTC Pharmaceuticals Forecast, 2009-2014
    • Table 3.28 Bayer Aspirin Formulations, 2009
    • Table 3.29 Bayer Aspirin Sales Forecast, 2009-2014
    • Table 3.30 Bayer Aspirin Sales Forecast, 2015-2024
    • Table 3.31 Novartis OTC Brands: 2008 Sales Revenues and Market Share
    • Table 3.32 Novartis Total OTC Pharmaceuticals Forecast, 2009-2014
    • Table 3.33 Novartis OTC Nicotine Replacement Therapy Products, 2009
    • Table 3.34 Proctor & Gamble OTC Brands: 2008 Sales Revenues and Market Share
    • Table 3.35 Prilosec OTC Sales Forecast, 2009-2014
    • Table 3.36 Prilosec OTC Sales Forecast, 2015-2024
    • Table 3.37 Vicks US Formulations, 2009
    • Table 3.38 Vicks Sales Forecast, 2009-2014
    • Table 3.39 Vicks Sales Forecast, 2015-2024
    • Table 3.40 Wyeth OTC Brands: 2008 Sales Revenues and Market Share
    • Table 3.41 Advil North American Formulations, 2009
    • Table 3.42 Advil Sales Forecast, 2009-2014
    • Table 3.43 Advil Sales Forecast, 2015-2024
    • Table 3.44 Sanofi-Aventis OTC Brands: 2008 Sales Revenues and Market Share
    • Table 3.45 Reckitt Benckiser OTC Brands: 2008 Sales Revenues and Market Share
    • Table 3.46 Boehringer Ingelheim OTC Brands: 2008 Sales Revenues and Market Share
    • Table 4.1 Recent and Future Gastrointestinal OTC Switches
    • Table 4.2 Recent and Future Cough, Cold & Allergy OTC Switches
    • Table 4.3 Recent and Future Analgesic OTC Switches
    • Table 4.4 Recent and Future Dermatological OTC Switches
    • Table 4.5 Other Possible Future OTC Switches
    • Table 5.1 SWOT Analysis of the OTC Pharmaceutical Sector, 2009
    • Table 5.2 World Population Forecast, 2008-2024
    • Table 5.3 Population Forecasts in Leading OTC Markets, 2008 & 2024
    • Table 5.4 GDP Forecast for Leading OTC Markets, 2008-2024
    • Table 6.1 OTC Revenues in Leading OTC Country Markets, 2008
    • Table 6.2 Leading OTC Country Markets Forecasts, 2009-2024
  • List of Figures
    • Figure 2.1 The OTC Pharmaceutical Supply Chain
    • Figure 3.1 OTC and Prescription-Only Pharmaceutical Markets, 2008
    • Figure 3.2 World OTC Pharmaceuticals Sales Forecast, 2009-2024
    • Figure 3.3 OTC Therapies (inc. Vitamins and Minerals) Revenues and Market Shares, 2008
    • Figure 3.4 OTC Category Revenues and Market Share, 2008
    • Figure 3.5 OTC Category Sales Forecast, 2009-2024
    • Figure 3.6 OTC Category Market Share Forecast, 2009-2024
    • Figure 3.7 Top Ten OTC Pharmaceutical Manufacturers, 2008
    • Figure 3.8 Top Ten OTC Manufacturers? Market Shares, 2008
    • Figure 3.9 Johnson & Johnson OTC Brands: 2008 Market Share
    • Figure 3.10 Johnson & Johnson Total OTC Pharmaceuticals Sales Forecast, 2009-2014
    • Figure 3.11 Tylenol Sales Forecast, 2009-2024
    • Figure 3.12 Nicorette (Johnson & Johnson) Sales Forecast, 2009-2024
    • Figure 3.13 GSK OTC Brands: 2008 Market Share
    • Figure 3.14 GSK Total OTC Pharmaceuticals Sales Forecast, 2009-2014
    • Figure 3.15 Panadol Sales Forecast, 2009-2024
    • Figure 3.16 Nicabate/NicoDerm/Nicorette/NiQuitin (GSK) Sales Forecast, 2009-2024
    • Figure 3.17 alli Sales Forecast, 2009-2024
    • Figure 3.18 Bayer OTC Brands: 2008 Market Share
    • Figure 3.19 Bayer Total OTC Pharmaceuticals Sales Forecast, 2009-2014
    • Figure 3.20 Bayer Aspirin Sales Forecast, 2009-2024
    • Figure 3.21 Novartis OTC Brands: 2008 Market Share
    • Figure 3.22 Novartis Total OTC Pharmaceuticals Sales Forecast, 2009-2014
    • Figure 3.23 Proctor & Gamble OTC Brands: 2008 Market Share
    • Figure 3.24 Prilosec OTC Sales Forecast, 2009-2024
    • Figure 3.25 Vicks Sales Forecast, 2009-2024
    • Figure 3.26 Wyeth OTC Brands: 2008 Market Share
    • Figure 3.27 Advil Sales Forecast, 2009-2024
    • Figure 3.28 Sanofi-Aventis OTC Brands: 2008 Market Share
    • Figure 3.29 Reckitt Benckiser OTC Brands: 2008 Market Share
    • Figure 3.30 Boehringer Ingelheim OTC Brands: 2008 Market Share
    • Figure 5.1 World Population Forecast, 2008-2024
    • Figure 5.2 Forecasted World Population Aged 65 or Over, 2008-2024
    • Figure 5.3 Population Forecasts in Leading OTC Markets, 2008 & 2024
    • Figure 5.4 GDP Forecast for Leading OTC Markets, 2008-2024
    • Figure 6.1 Market Share of Leading OTC Country Markets, 2008
    • Figure 6.2 Forecast Market Share of Leading OTC Country Markets, 2014
    • Figure 6.3 Forecast Market Share of Leading OTC Country Markets, 2019
    • Figure 6.4 Forecast Market Share of Leading OTC Country Markets, 2024
    • Figure 7.1 World OTC Pharmaceuticals Sales Forecast, 2009-2024
      • Companies Listed
      • Alliance Boots, Abbott, Adams Respiratory Therapeutics (Reckitt Benckiser), American Medical Association, AmerisourceBergen, AstraZeneca, AZ Tika (AstraZeneca), Barr (Teva), Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardinal Health, Celesio, Chattem, CNS (GSK), Daiichi Sankyo, Dexcel, Dr. Reddy?s Laboratories, Eisai, European Medicines Agency (EMEA), Federal Trade Commission (US), Food and Drug Administration (FDA) (US), Galpharm (Perrigo), GlaxoSmithKline (GSK), Johnson & Johnson, Kowa, Lion, McKesson, Medicines and Healthcare products Regulatory Agency (MHRA) (UK), Menarini, Merck & Co., Ministry of Health, Labour and Welfare (MHLW) (Japan), Mylan, Novartis, Nycomed, Perrigo, Pfizer, Phoenix, Proctor & Gamble, Public Citizen (US), Ranbaxy, Ratiopharm, Reckitt Benckiser, Roche, Rohto, Sagmel (Bayer), Sanofi-Aventis, Santarus, Sato, Schering-Plough, SSL International, SSP, Sun, Symbion Consumer (Sanofi-Aventis), Taisho, Takeda, Target, Teva, Therapeutic Goods Administration (TGA) (Australia), Topsun (Bayer), Walmart, Wyeth